Stanziale, Jr. v. Medi Biotech, LLC

CourtUnited States Bankruptcy Court, D. Delaware
DecidedMarch 20, 2025
Docket18-50400
StatusUnknown

This text of Stanziale, Jr. v. Medi Biotech, LLC (Stanziale, Jr. v. Medi Biotech, LLC) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Stanziale, Jr. v. Medi Biotech, LLC, (Del. 2025).

Opinion

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE ‘de eB) 2 JOHN T. DORSEY 5 ae S, 824 N. MARKET STREET JUDGE prog WILMINGTON, DELAWARE . (302) 533-3169 ae ue March 20, 2025 Plaintiff's and Defendant’s counsel via CM/ECF Re: Stanziale v. Medi Biotech LLC, Adv. Proc. Nos. 18-50400 and 18-504014 Dear Counsel, This letter is my ruling on Braverman Brothers’ Motions to Dismiss the Amended Complaints (the “Motions”), filed by Defendant Braverman Brothers, LLC (“Braverman”).” For the reasons explained below, the Motions are denied. Background Charles A. Stanziale, Jr. is the Chapter 7 Trustee (““Trustee”’) of the bankruptcy estates of Main Avenue Pharmacy, Inc. (“Main”) and ScripsAmerica, Inc. (““SCRC’”) (collectively “Debtors”). Braverman is a Florida Limited Liability Company that marketed the Debtors’ compounded prescription products in 2014 and 2015. The Debtors made certain payments to Braverman based on a percentage of the amount the Debtors received from pharmaceutical benefits managers (“PBMs”), such as Optum, Caremark, and Express Scripts. On September 7, 2016, SCRC filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code. The case was converted to a Chapter 7 on February 7, 2017. On July 21, 2017, Main filed a voluntary petition for relief under Chapter 7 of the Bankruptcy Code. An order for joint administration of the Debtors’ cases was entered on September 15, 2017.

' The Trustee filed two separate adversary proceedings. One on behalf of ScripsAmerica, Inc., (Case No. 18-50400), and one on behalf of Main Avenue Pharmacy, Inc. (Case No. 18-50401). The allegations in the complaints against Braverman are identical, and Braverman filed identical motions to dismiss in both cases. 2 Case No. 18-50400 Adv. D.I. 35 & 44; Case No. 18-50401 Adv. D.I. 41 & 53.

On April 17, 2018, the Trustee filed the adversary complaints against Braverman among others.3 The Trustee amended his complaints on June 26, 2018.4 The Amended Complaints seek to avoid and recover several allegedly fraudulent transfers from the Debtors to Braverman pursuant to the Bankruptcy Code, the Delaware Uniform Fraudulent Transfer Act (“DUFTA”), and the New Jersey Uniform Fraudulent Transfer Act (“NJUFTA”).5 Additionally, the Amended Complaints include a claim for unjust enrichment against Braverman.6

Braverman moved to dismiss all claims against it for failure to state a claim. The Trustee filed his objections to the Motions on October 29, 2018.7 The parties declined the option to update their briefing in February of 2025.8

Discussion A motion to dismiss pursuant to Federal Rule of Civil Procedure 12(b)(6)—made applicable to bankruptcy proceedings pursuant to Federal Rule of Bankruptcy Procedure 7012(b)—serves to test the sufficiency of the complaint, and a court’s role is to determine whether the plaintiff is entitled to offer evidence in support of its claims. Semerenko v. Cendant Corp., 223 F.3d 165, 173 (3d Cir. 2000); Paul v. Intel Corp. (in re Intel Corp. Microprocessor Antitrust Litig.), 496 F. Supp. 2d 404, 407 (D. Del. 2007) (citing Kost v. Kozakiewicz, 1 F.3d 176, 183 (3d Cir. 1993). To survive a motion to dismiss, a plaintiff must allege well-pleaded facts with sufficient detail to “state a claim for relief that is plausible on its face.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007); Fowler v. UPMC Shadyside, 578 F.3d 203, 210 (3d Cir. 2009) (citing Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009)). The Third Circuit has adopted a two-part analysis that courts must employ when deciding a Rule 12(b)(6) motion. Fowler, 578 F.3d at 210. “First, the factual and legal elements of a claim should be separated” with the reviewing court accepting “all of the complaint’s well-pleaded facts as true, but . . . disregard[ing] any legal conclusions.” Id. at 210-11. Next, the reviewing court must “determine whether the facts alleged in the complaint are sufficient to show that the plaintiff has a ‘plausible claim for relief.’” Id. (quoting Iqbal, 556 U.S. at 679); Gellert v. Coltec Indus., Inc. (In re Crucible Materials Corp.), Nos. 09-11582 & 11-53885, 2012 WL 5360945, at

3 Case No. 18-50400 Adv. D.I. 1, and Case No. 18-50401 Adv. D.I. 1. 4 Case No. 18-50400 Adv. D.I. 12, and Case No. 18-50401 Adv. D.I. 12. (“Amended Complaints”). 5 Amended Complaints, Count 2 (¶¶51-74) (avoidance of fraudulent conveyances pursuant to 11 U.S.C. § 544(b) and 6 Del. C. § 1304(a)); id., Count 3 (¶¶75-83) (avoidance of fraudulent conveyances pursuant to 11 U.S.C. § 544(b) and 6 Del. C. §1305(a)); id., Count 4 (¶¶84-98) (avoidance of fraudulent conveyances pursuant to 11 U.S.C. § 544(b) and N.J.S.A. 25:2-25); id., Count 5 (¶¶99-107) (avoidance of fraudulent conveyances pursuant to 11 U.S.C. § 544(b) and N.J.S.A. 25:2-27(a)); id., Count 6 (recovery of avoided transfers pursuant to 11 U.S.C. § 550). 6 Amended Complaints, Count 8 (¶¶117-122). 7 Trustee’s Objection to Braverman Brothers’ Motions to Dismiss the Amended Complaints, Case No. 18- 50400 Adv. D.I. 59, and Case No. 18-50401 Adv. D.I. 59. (“Trustee’s Objection”). 8 The parties requested at least twenty-four continuances of the pretrial conference as they tried to mediate a settlement. The mediation attempts were ultimately unsuccessful. *3 (Bankr. D. Del. Oct. 31, 2012). “The plausibility standard is not akin to a ‘probability requirement,’ but it asks for more than a sheer possibility that a defendant has acted unlawfully.” Iqbal, 556 U.S. at 679. “Where the well-pleaded facts do not permit the court to infer more than the mere possibility of misconduct, the complaint has alleged—but it has not ‘show[n]’—‘that the pleader is entitled to relief.” Id. at 679 (internal citations omitted). This “plausibility” determination will be “a context-specific task that requires the reviewing court to draw on its judicial experience and common sense.” Id. Braverman makes three arguments as to why the Complaints should be dismissed: (1) they fail to state a claim for fraudulent conveyance under the Bankruptcy Code; (2) they fail to state a claim for fraudulent conveyance under applicable state law; and (3) they fail to state a claim for unjust enrichment. With respect to its first argument, Braverman argues that the complaints do not allege a claim under sections 544(b) and 548 of the Bankruptcy Code. Specifically, Braverman argues that the Amended Complaints do not address the value of the services it provided to the Debtors and that they do not allege that the commissions were disproportionate to like commissions paid for similar services in the marketplace; instead, Braverman argues, the Complaints contain only general statements that the payments were excessive.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Fowler v. UPMC SHADYSIDE
578 F.3d 203 (Third Circuit, 2009)
Hartman v. Harris
810 F. Supp. 82 (S.D. New York, 1992)
Redmond v. Kester (In Re Kester)
339 B.R. 749 (Tenth Circuit, 2006)
In Re Intel Corp. Microprocessor Antitrust Lit.
496 F. Supp. 2d 404 (D. Delaware, 2007)
VFB LLC v. Campbell Soup Co.
482 F.3d 624 (Third Circuit, 2007)
Kost v. Kozakiewicz
1 F.3d 176 (Third Circuit, 1993)
Tabas v. Lehman (In re Capitol Investments, Inc.)
473 B.R. 838 (S.D. Florida, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
Stanziale, Jr. v. Medi Biotech, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/stanziale-jr-v-medi-biotech-llc-deb-2025.